Treatment Pathways and Candidate Correlates of Surgical Intervention in Locally Advanced Cervical and Other Gynecological Cancers: A Hypothesis-Generating Single-Center Cohort Study

Alexandru Orasan, Nicolae Constantin Balica, Adrian Mihail Sitaru, Mihaela Cristina Negru, Anda Ioana Morgovan, Kristine Guran, Andreea Mihaela Banta, Sebastian Ciurescu, Mihaela-Iuliana Sirbu, Eugen Horatiu Stefanescu · 2026

Read Treatment Pathways and Candidate Correlates of Surgical Intervention in Locally Advanced Cervical and Other Gynecological Cancers: A Hypothesis-Generating Single-Center Cohort Study by Alexandru Orasan, Nicolae Constantin Balica, Adrian Mihail Sitaru, Mihaela Cristina Negru, Anda Ioana Morgovan, Kristine Guran, Andreea Mihaela Banta, Sebastian Ciurescu, Mihaela-Iuliana Sirbu, Eugen Horatiu Stefanescu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607512.txt.

Introduction

Alexandru Orasan and nine others map treatment paths in advanced cervical and related cancers, probing what predicts surgery, in a 2026 exploratory study. Standard care leans on chemotherapy plus radiation, saving surgery for salvage. The team studied sixty-nine patients at a Romanian center over one year.

Patients fell into three protocol groups: dose-dense induction therapy, classic three-weekly therapy, or no induction. Most in each group then got chemoradiation. A quarter had some surgery, but none came from the dose-dense group. That group had the shortest follow-up and started out unlike the others. The team's model sorted cases only fairly well. Urban origin, dose deviation, and cycle count leaned toward showing who had surgery, but none reached significance. The authors stress the work is hypothesis-generating, not a prediction tool. They name where patients live and treatment deviation as factors worth testing in future trials.

Catalog record

CREATORAlexandru Orasan, Nicolae Constantin Balica, Adrian Mihail Sitaru, Mihaela Cristina Negru, Anda Ioana Morgovan, Kristine Guran, Andreea Mihaela Banta, Sebastian Ciurescu, Mihaela-Iuliana Sirbu, Eugen Horatiu Stefanescu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13607512

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Treatment Pathways and Candidate Correlates of Surgical Intervention in Locally Advanced Cervical and Other Gynecological Cancers: A Hypothesis-Generating Single-Center Cohort Study Authors: Alexandru Orasan, Nicolae Constantin Balica, Adrian Mihail Sitaru, Mihaela Cristina Negru, Anda Ioana Morgovan, Kristine Guran, Andreea Mihaela Banta, Sebastian Ciurescu, Mihaela-Iuliana Sirbu, Eugen Horatiu Stefanescu Published: 2026 ABSTRACT Background/Objectives: Management of locally advanced cervical cancer (LACC) and other gynecological malignancies aims to achieve locoregional control while avoiding morbid surgical salvage. This exploratory, hypothesis-generating study described the treatment pathways of three protocol groups and examined whether clinical, sociodemographic, and treatment-deviation variables are associated with any oncological surgery. Methods: Sixty-nine adult patients with gynecological or urogenital cancers (89.9% cervical carcinoma) treated with platinum-based chemotherapy at a Romanian tertiary center between April 2024 and April 2025 were stratified into INTERLACE-type dose-dense induction chemotherapy followed by chemoradiotherapy (Group A, n = 27), classic three-weekly neoadjuvant chemotherapy followed by chemoradiotherapy (Group B, n = 7), and no induction chemotherapy (Group C, n = 35). Associations with any oncological surgery (upfront, completion, or salvage) were explored by multivariable logistic regression with bootstrap internal validation, Firth penalized regression, and restricted sensitivity analyses. Results: Twenty-five patients (36.2%) underwent surgery (14 upfront, 8 completion, 3 salvage), and none of them were from Group A, whose median follow-up was only 8.6 months and whose allocation was confounded by diagnosis and stage. The model showed an apparent area under the curve of 0.717 (optimism-corrected 0.672), accuracy of 73.9% against a no-information rate of 63.8% (p = 0.049), sensitivity of 0.480, and specificity of 0.886. Urban provenience (OR 0.343, 95% CI 0.113–1.039, p = 0.059), Delta Target Dose (OR 1.109 per Gy, p = 0.076), and number of chemotherapy cycles (OR 1.298 per cycle, p = 0.076) showed non-significant trends whose direction was unchanged in all sensitivity analyses. Conclusions: The absence of surgery after induction chemotherapy is hypothesis-generating rather than confirmatory, and the exploratory model is not a clinical prediction tool. Geographic provenience and planning-to-delivery treatment deviation are candidate variables for prospective evaluation in a homogeneous LACC population with standardized radiotherapy parameters and mature oncological endpoints. 1. Introduction Cervical cancer remains the fourth most frequent cancer in women worldwide, with an estimated 660,000 new cases and 350,000 deaths in 2022 [1], and its burden is concentrated in regions where screening coverage is low and a large proportion of patients present with locally advanced disease, as is the case in Romania [2,3]. The global conceptual framework for managing locally advanced cervical cancer (LACC) and other locally advanced gynecological malignancies rests on definitive concurrent platinum-based chemoradiotherapy (CCRT) with image-guided brachytherapy, which has been the standard of care since the demonstration that concurrent cisplatin improves survival over radiotherapy alone [4,5,6,7,8]. Image-guided adaptive brachytherapy has since further improved pelvic control and survival in large multicenter cohorts [9,10]. In this paradigm, chemoradiotherapy is itself the definitive treatment, and surgery is reserved for three clinically distinct situations: planned upfront surgery in early-stage or selected non-cervical disease, where fertility-sparing options may also be considered [11], completion surgery for histologically or radiologically confirmed residual disease after chemoradiotherapy, and salvage surgery for locoregional recurrence [4,12,13]. Completion and salvage procedures in a previously irradiated pelvis, up to and including pelvic exenteration, carry substantial morbidity, so that avoiding them without compromising local control is a central objective of multidisciplinary management [12,13,14,15,16]. Chemotherapy treatment intensity (CTI), understood here as the schedule, dose density, and number of platinum-containing cycles delivered before and during radiotherapy, has re-emerged as a modifiable determinant of outcome. The number of concurrent cisplatin cycles is independently associated with survival after CCRT [17], and the interaction between the number of cycles and brachytherapy dose–volume parameters influences local control [18]. Most importantly, the GCIG INTERLACE phase 3 trial showed that six weekly cycles of dose-dense carboplatin and paclitaxel given immediately before standard CCRT improve progression-free and overall survival in LACC [19,20], whereas conventional three-weekly neoadjuvant chemotherapy followed by radical surgery did not outperform CCRT in two randomized comparisons [21,22]. More recently, the addition of pembrolizumab to CCRT improved overall survival in high-risk LACC [23], confirming that intensification of the definitive non-surgical pathway, rather than a return to radical surgery, is the direction of current standard-setting trials. The INTERLACE regimen was adopted by our tumor board in 2024 for eligible patients with LACC; the two other pathways in use during the study period were a classic three-weekly neoadjuvant platinum–taxane protocol followed by CCRT and a no-induction pathway consisting of upfront surgery or definitive CCRT [4,19,21]. Whether patients ultimately require surgery after these pathways is also shaped by factors outside the tumor. In Romania, cervical cancer mortality remains among the highest in Europe and displays marked rural–urban inequalities [24], and geography has been proposed as an independent prognostic and decision-making factor [25,26]. Physical treatment quality is a further candidate: the dose actually delivered to the target may deviate from the dose prescribed at planning because of anatomical change, adaptive replanning, treatment interruptions, or incomplete brachytherapy, and interfraction dose variations have been linked to clinical outcome [27,28]. Within the EMBRACE framework, tumor dose, target volume, and overall treatment time are established determinants of local control after chemoradiotherapy with brachytherapy [29], so that deviations between planned and delivered treatment are a legitimate object of study even when they are measured coarsely. The present study is explicitly exploratory and hypothesis-generating. Its objectives were (i) to describe the treatment pathways and surgical outcomes of three protocol groups treated at a single Romanian tertiary center during the first year of INTERLACE-type induction chemotherapy; (ii) to characterize the radiotherapy component of treatment; and (iii) to explore, in a multivariable model with internal validation and pre-specified sensitivity analyses, whether geographic provenience, age, planning-to-delivery treatment deviation (Delta Target Dose, an exploratory institutional treatment-deviation metric), and chemotherapy intensity (an exploratory correlate) are associated with the need for any oncological surgery. Given the sample size, the heterogeneity of the cohort, and the short follow-up, the study does not aim to deliver a clinical prediction tool but to identify candidate variables for a subsequent prospective study in a homogeneous LACC population. 2. Materials and Methods 2.1. Study Design and Setting We conducted a single-center, observational, hypothesis-generating cohort study at a tertiary oncology center in Timișoara, Romania. Consecutive adult patients with a histologically confirmed gynecological or urogenital malignancy who started platinum-based chemotherapy between 1 April 2024 and 1 April 2025 were enrolled prospectively in an institutional registry, with a data lock on 1 April 2025. The study was conducted in accordance with the Declaration of Helsinki and its later amendments and was approved by the Institutional Review Board of the Victor Babes University of Medicine and Pharmacy Timișoara (approval no. 30, dated 19 April 2024) before the first patient was enrolled. All patients gave written informed consent for treatment, for inclusion in the institutional registry, and for the use of their pseudonymized clinical, dosimetric, and imaging data for research purposes; consent could be withdrawn at any time without consequences for care. Data were pseudonymized at extraction, stored on a password-protected institutional server in accordance with the General Data Protection Regulation (EU 2016/679), and accessed only by the investigators named in the protocol. No patient-identifying information is reported. Reporting follows the TRIPOD recommendations for exploratory

Read the complete text